Valuation Haemonetics Corporation
Stocks
HAE
US4050241003
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
16:04:45 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 108.40 USD | +0.74% |
|
+5.56% | +35.25% |
| 09-17 | Haemonetics Shares Rise After Citigroup Upgrade | MT |
| 09-17 | Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92 | MT |
Company Valuation: Haemonetics Corporation
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,068 | 3,992 | 4,335 | 3,175 | 2,511 | 4,932 | - | - |
| Change | - | 30.13% | 8.58% | -26.76% | -20.89% | 96.39% | - | - |
| Enterprise Value (EV) 1 | 3,582 | 4,473 | 4,335 | 4,093 | 3,490 | 5,594 | 5,259 | 4,901 |
| Change | - | 24.89% | -3.1% | -5.58% | -14.71% | 60.26% | -5.99% | -6.82% |
| P/E | 71.5x | 35.3x | 37.3x | 19.1x | 26.4x | 27.4x | 24.1x | 20.8x |
| PBR | 4.09x | 4.88x | - | 3.71x | 3.21x | 4.64x | 3.61x | 2.91x |
| PEG | - | 0x | 16.71x | 0.4x | -0.7x | 0.3x | 1.8x | 1.3x |
| Capitalization / Revenue | 3.09x | 3.42x | 3.31x | 2.33x | 1.88x | 3.48x | 3.3x | 3.08x |
| EV / Revenue | 3.61x | 3.83x | 3.31x | 3.01x | 2.62x | 3.95x | 3.52x | 3.06x |
| EV / EBITDA | 12.6x | 14.7x | 11.7x | 9.67x | 7.93x | 12.4x | 10.7x | 8.66x |
| EV / EBIT | 19.1x | 20.5x | 15.7x | 12.5x | 10.3x | 15.2x | 13.2x | 11.1x |
| EV / FCF | - | - | 37.5x | 33.7x | 13.4x | 17.6x | 15.7x | 13.7x |
| FCF Yield | - | - | 2.66% | 2.96% | 7.46% | 5.67% | 6.37% | 7.31% |
| Dividend per Share 2 | - | - | - | - | - | 1 | - | - |
| Rate of return | - | - | - | - | - | 0.92% | - | - |
| EPS 2 | 0.84 | 2.24 | 2.29 | 3.31 | 2.05 | 3.963 | 4.507 | 5.21 |
| Distribution rate | - | - | - | - | - | 25.2% | - | - |
| Net sales 1 | 993.2 | 1,169 | 1,309 | 1,361 | 1,334 | 1,417 | 1,495 | 1,599 |
| EBITDA 1 | 284.9 | 304.7 | 370.1 | 423.3 | 440.1 | 452.5 | 491.8 | 565.6 |
| EBIT 1 | 187.1 | 218.4 | 276.5 | 326.3 | 338.5 | 368.2 | 399 | 440.2 |
| Net income 1 | 43.38 | 115.4 | 117.6 | 167.7 | 97.31 | 177.4 | 207.2 | 239.6 |
| Net Debt 1 | 514.1 | 481.4 | - | 918 | 979.1 | 662 | 327.1 | -31.34 |
| Reference price 2 | 60.02 | 79.13 | 85.35 | 63.19 | 54.04 | 108.40 | 108.40 | 108.40 |
| Nbr of stocks (in thousands) | 51,112 | 50,448 | 50,786 | 50,237 | 46,471 | 45,497 | - | - |
| Announcement Date | 5/10/22 | 5/11/23 | 5/9/24 | 5/8/25 | 5/7/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.35x | 3.95x | 12.36x | 0.92% | 4.93B | |
| 29.07x | 4.01x | 15.51x | 2.51% | 178B | |
| 19.49x | 3.56x | 12.71x | 3.06% | 118B | |
| 16.91x | 0.2x | 12.41x | 0.77% | 58.92B | |
| 34.87x | 3.38x | 11.58x | 2.17% | 49.29B | |
| 27.56x | 6.78x | 17.54x | 1.45% | 48.17B | |
| 35.82x | 6.3x | 19.78x | -.--% | 33.72B | |
| 40.85x | 1.21x | 11.23x | 0.23% | 27.76B | |
| 42.25x | 7.41x | 26.57x | 0.25% | 25.5B | |
| 50.52x | 6.81x | 21.88x | 0.42% | 22.1B | |
| Average | 32.47x | 4.36x | 16.16x | 1.18% | 56.58B | |
| Weighted average by Cap. | 28.58x | 3.96x | 15.20x | 1.86% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- HAE Stock
- Valuation Haemonetics Corporation
Select your edition
All financial news and data tailored to specific country editions
